Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

17.5K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diverse germline-targeting HIV Env immunogens select for distinct mutations in the same knock-in mice B cell receptors.

Nature communications·2026
Same author

The N-terminal region of malaria vaccine candidate asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies.

Disease models & mechanisms·2026
Same author

Humanized mice enable <i>in vivo</i> evaluation of engineered plasma cell biology and therapeutic function.

Molecular therapy. Advances·2026
Same author

How Vaccinating People Living With HIV May Guide bNAb‑Based Vaccines.

Journal of the International AIDS Society·2026
Same author

Antibody-mediated diversification of primary and secondary humoral immune responses.

The Journal of experimental medicine·2026
Same author

B lymphocyte protein factories produced by hematopoietic stem cell gene editing.

Science (New York, N.Y.)·2026
Same journal

Diversity, Equality, and Inclusion in the naïve T Cell Receptor Repertoire.

Immunological reviews·2026
Same journal

Macrophage Plasticity and Immune Remodeling in Ischemic Heart Failure.

Immunological reviews·2026
Same journal

The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.

Immunological reviews·2026
Same journal

Tissue-Resident Memory T Cells in the Heart: An Emerging Role in Chronic Inflammation.

Immunological reviews·2026
Same journal

Rethinking Immunity in Tissues: The Biology of Tertiary Lymphoid Structures.

Immunological reviews·2026
Same journal

Inflammation-Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity.

Immunological reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Germline-targeting immunogens.

Leonidas Stamatatos1,2, Marie Pancera1, Andrew T McGuire1

  • 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Immunological Reviews
|January 31, 2017
PubMed
Summary
This summary is machine-generated.

Early HIV-1 broadly neutralizing antibodies (bNAbs) in their inferred germline forms showed no binding to Env proteins. This finding led to the development of germline-targeting immunization strategies for effective bNAb induction.

Keywords:
HIVB-cell receptorsEnvgermline antibodiesimmunogens

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K

Related Experiment Videos

Last Updated: Mar 8, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • Inferred germline (iGL) forms of HIV-1 broadly neutralizing antibodies (bNAbs) initially showed no measurable binding to recombinant gp140 Env proteins.
  • Subsequent advancements in high-throughput assays enabled the isolation of more bNAbs and diverse Env proteins.

Purpose of the Study:

  • To review the germline-targeting immunization approach for eliciting bNAbs against HIV-1.
  • To discuss the progress, advantages, and limitations of current germline-targeting immunogens and animal models.

Main Methods:

  • Confirmation of Dimitrov's group observations using newly isolated bNAbs and diverse recombinant Envs.
  • Review and discussion of existing germline-targeting strategies and relevant animal models.

Main Results:

  • The initial observation that iGL bNAbs do not bind to standard recombinant Envs was confirmed.
  • These findings shifted the paradigm towards germline-targeting immunization strategies.

Conclusions:

  • The germline-targeting approach represents a significant advancement in HIV-1 vaccine research.
  • Further research is needed to optimize immunogens and animal models for effective bNAb induction.